What are the clinical features, diagnostic criteria, and recommended treatment for Wiskott‑Aldrich syndrome?

Wiskott-Aldrich Syndrome: Clinical Overview and Management

Consider Wiskott-Aldrich syndrome (WAS) in all male patients presenting with clinically significant thrombocytopenia and characteristically small platelets (3.8-5.0 fL), and pursue hematopoietic stem cell transplantation (HSCT) or gene therapy as definitive treatment for most patients at diagnosis, as even milder phenotypes carry substantial risk of severe immune complications. 1, 2

Clinical Features

Classic Triad and Presentation

WAS presents with X-linked inheritance and the following manifestations 1:

• Thrombocytopenia with small platelets: The most consistent finding

  • Platelet volumes: 3.8-5.0 fL (normal: 7.1-10.5 fL)
  • Homogeneous small platelet size distinguishes WAS from other thrombocytopenias
  • Manifests as petechiae, bruising, and bleeding

• Eczema: Variable severity (absent, mild, or severe)

• Recurrent infections:

  • Sinopulmonary bacterial infections (otitis, sinusitis)
  • Frequent viral illnesses
  • Opportunistic infections including Pneumocystis jirovecii pneumonia (PCP), indicating severe immune compromise

Progressive Complications

Without curative therapy, patients most often succumb to overwhelming infection or massive hemorrhage 1:

• Autoimmune disease (observed in older patients):

  • Autoimmune colitis
  • Vasculitis and glomerulonephritis
  • Other autoimmune processes

• Malignancy (10-15% of patients):

  • Average age of onset: ~10 years

  • 80% are lymphomas, often EBV-associated 1

Disease Spectrum

The initial presentation may be limited to bruising and bleeding (historically termed X-linked thrombocytopenia or XLT), but this terminology should be discontinued as it falsely implies mild, uncomplicated disease 2. In a multicenter study of 173 XLT patients with WAS gene mutations 1:

• Serious infections: 7%
• Autoimmunity: 12%
• Malignancy: 5%

Diagnostic Criteria

Laboratory Confirmation

Small platelet size confirms the diagnosis in the appropriate clinical context 1:

1. Blood smear examination: Essential when automated counters report normal platelet size

   • Look for homogeneously small platelets
   • Note: 20% of WAS patients can develop immune thrombocytopenia before or after splenectomy

2. Definitive molecular diagnosis 1:

   • WAS gene mutation analysis (required)
   • WAS protein (WASp) expression by flow cytometry or Western blot
   • Abnormal findings are diagnostic with characteristic clinical features
   • Caveat: Normal WASp size/amount doesn't exclude diagnosis—some point mutations permit protein production, requiring molecular analysis

Immunologic Abnormalities

Humoral defects 1:

• Variable dysgammaglobulinemia
• Normal or low IgG and/or IgM levels
• Normal or increased IgA levels
• Variable IgE levels

• 50% have impaired vaccine antibody responses or isohemagglutinin production

• May not appear until late in disease course

Cellular defects 1:

• T-cell lymphopenia (20-30% of patients)
• Disproportionately decreased CD8+ T cells (>50% of patients)
• Reduced T-cell proliferation to mitogens (33-50% of patients)
• Diminished cutaneous antigen responses (>80% of patients)
• Decreased NK cell cytotoxic function

Treatment Approach

Definitive Therapy: The Primary Recommendation

HSCT or gene therapy should be offered to most young WAS patients at diagnosis 2. This represents a paradigm shift from historical practice:

• Rationale: Recent evidence confirms that even patients with milder genetic variants are at risk for severe immune complications, autoimmunity, and malignancy
• Timing: Early intervention prevents irreversible complications
• Outcomes: Advances in HSCT and gene therapy have significantly improved survival and reduced morbidity 2, 3, 4

Conservative Management: Limited Role

Reserved only for older patients with a small subset of milder variants who have not developed life-threatening complications 2:

Supportive care components:

1. Infection prophylaxis:

   • PCP prophylaxis (mandatory for all WAS patients) 1
   • Lifelong antibiotic prophylaxis if splenectomized
   • Immunoglobulin replacement as needed
   • Vaccination (with additional booster doses for protective titers) 1

2. Bleeding management:

   • Avoid antiplatelet agents and NSAIDs
   • Platelet transfusions for severe bleeding (use irradiated, CMV-negative products)

3. Eczema treatment: Standard dermatologic management

4. Regular monitoring: Critical to detect autoimmune complications or malignancy early

Splenectomy: Highly Restricted Role

Splenectomy is now largely obsolete in the era of HSCT and gene therapy 5, with use restricted to:

1. Bridge to HSCT: Severe, refractory thrombocytopenia with life-threatening bleeding
2. Rescue option: When HSCT/gene therapy are inaccessible (resource-limited settings)
3. Post-HSCT intervention: Persistent thrombocytopenia from mixed donor chimerism

Critical limitations 5:

• Does not correct underlying immune defect
• Substantial risk of overwhelming infection
• Requires lifelong antibiotic prophylaxis
• Relapse occurs in up to 56% of classical WAS cases within first year
• Benefits must clearly outweigh risks

Neutropenia Management

If neutropenia develops, treat with G-CSF, but discontinue periodically to assess ongoing necessity as neutropenia can resolve spontaneously 1. Note increased risk of myeloid proliferation or leukemia with prolonged G-CSF therapy.

Clinical Pitfalls

1. Misdiagnosis as chronic ITP: WAS patients often lack the complete triad and present primarily with thrombocytopenia. In one screening study, 13.5% of boys with chronic ITP had pathogenic WAS variants 6. Always check MPV and consider WAS in males with chronic ITP, especially with X-linked family history, eczema, low MPV, or suboptimal response to immunomodulatory drugs.

2. Relying on automated platelet counts: Automated counters may report normal platelet size—always examine blood smear directly 1

3. Assuming "XLT" is benign: This outdated terminology creates false reassurance. Tailor treatment to individual genetic profile and clinical course 2

4. Delaying definitive therapy: Waiting for complications to develop before pursuing HSCT/gene therapy increases morbidity and mortality. Early intervention is key 2

5. Overlooking autoimmune complications: Regular monitoring is essential as autoimmune disease develops in older patients and can be life-threatening 1